Microsoft word - the dietary supplements market outlook - final.doc
OutlookThe impact of changes in regulation, demographics and
Mark J Tallon, PhD
Dr Mark J. Tallon received his Ph.D. in nutritional biochemistry from Southampton
University and also holds a first degree in exercise physiology and a Masters degree in
nutrition science. He has worked as a key consultant to many companies including
Yuki Gosei Koga Ltd, Miami Research Associates, Natrol Inc, Labrada Inc, and iSatori
Global Laboratories. Until recently, Dr Tallon was Chief Science Officer of Oxygenix
Ltd, a consultancy company specializing in European, Pan-American and Asian
regulatory compliance of dietary supplements. He was co-founder of Cr-Technologies,
LLP, a raw ingredient company specializing in novel and proprietary nutraceuticals for
the cosmetic, dietary and functional food market. He is currently a research follow at
Northumbria University (UK) and a member of the Institute of Biology, Nutrition
Society of Great Britain and a member of the editorial board for the International
Society of Sports Nutrition (ISSN). Through these societies, Dr Tallon is currently
registered as a certified biologist and nutritionist. In 2007 Dr Tallon accepted
invitations to form part of the editorial advisory board for Food Ingredients Health and
Nutrition (UK) and Functional Ingredients magazine (US). Other affiliations include
the Institute of Food Technologists, American Botanical Council, and American
College of Nutrition, The Physiological Society and the American Medical Writers
Copyright 2007 Business Insights Ltd This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd. The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon. While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.
The Dietary Supplements Market Outlook Executive Summary Introduction 12 Market drivers and issues The supplements market Innovation and NPD Key and future trends in supplements Industry survey Conclusions Chapter 1 Introduction 20 Introduction 20 Research methodology What is this report about? The supplements market defined Chapter 2 Market drivers and issues Introduction 28 Factors affecting the growth of the industry
Regulatory issues – opportunities and threats for manufacturers
Chapter 3 The supplements market Introduction 50 Sales of supplements Chapter 4 Innovation and NPD Introduction 90 Innovation and NPD Category analysis
Whey gets blocked in China…A sign of things to come?
Regional analysis
Microencapsulation 118 Health claims in the US.Is the EFSA influencing the US?
Industry interview – insight into North America
Nanotechnology – big things come in small packages
Industry interview – insight into Europe
Economic recovery has not guaranteed success for supplement market 132 Innovation in the hands of weight loss and beauty
Chapter 5 Key and future trends in supplements 140 Introduction 141 Personalization 141 Demographic differentiation Emerging markets - the key to growth Immunity gathers momentum Obesity and cross-category-marketing Consumer trends – where is the market headed? The meta-analysis – “friend or foe” Visual differentiation through research
Industry interview – clinical research
Chapter 6 Industry survey Introduction 168 Supplements NPD Target audience Price premiums Regional potential Distribution channels Supplement categories Supplements versus food and drinks Impact of external factors on supplement NPD Launching a dietary supplement Marketing supplements Chapter 7 Conclusions 182 Introduction 182 Growth opportunities and resistance
Disease prevention and healthcare (self-medication)
Personalization 185 Purity and ingredient efficacy
Partnerships: making traditional and local insights work
Chapter 8 Appendix 190 References
Overview of Japanese regulatory system of dietary supplements
Phosphagen Elite from EAS containing Carnosyn beta-alanine 65
Advantra-Z (Citrus aurantium) from Nutratech
Percentage share of supplements launched, by category 2004 and 2007
Percentage growth of supplements launched, 2004 and 2007
DSM Nutritionals Teavigo seal of quality
MyAlli starter pack with Steven Burton, Vice President of the weight control unit 112
Cross channel growth in healthcare products GSK
Percentage share of supplements launched, by region, 2004 and 2007
Percentage share of supplements in each region, by category, 2007
Influence of a negative meta-analysis on Avandia
The importance of key health areas in supplements NPD over the next 5 years
Demographic groups that will be the most important for the growth of the supplements market over the next 5 years
Price premium consumers are willing to pay for a particular benefit
Regional growth potential for supplements manufacturers over the next 5 years
Sales growth potential in key distribution channels over the next 5 years
Supplements categories that will offer the most sales growth potential over the next 5 years 174
Future sales growth – from supplements or from use in food and drinks
Impact key factors will have on supplements NPD over the next 5 years
The importance of key factors for a successful launch of a dietary supplement
The importance of various forms of marketing for the launch of dietary supplements
Clarinol, Teavigo and Ocean Nutrition MEG-3
Sales of dietary supplements in the US, $m, 2002-2006
Per capita sales of dietary supplements in the US, $, 2002-2006
Sales of dietary supplements in Europe, $m, 2002-2006
Per capita sales of supplements, $, Europe, 2002-2006
Sales of dietary supplements in Japan, $m, 2002-2006
Per capita sales of supplements, $, Japan, 2002-2006
Official Journal of the European Communities TWENTY-FIFTH COMMISSION DIRECTIVE 2000/11/EC of 10 March 2000 adaptingto technical progress Annex II to Council Directive 76/768/EEC on the approximation of the laws of the Member States relatingto cosmetic products (Text with EEA relevance) THE COMMISSION OF THE EUROPEAN COMMUNITIES,Having regard to the Treaty establishing the European
Summary and Comment | TMS in Psychiatry Fall, 2013 Patients with MDD treated with rTMS still improved after 6 months Geoffrey Grammer MD reviewing Janicak PG, Nahas Z, Lisanby SH, Solvason HB Brain Stimul. 2010 Oct Conclusion In patients pharmacotherapy-resistant MDD who received rTMS, after 6 months, 10% of patients relapsed, and if they did experience clinical worsening, the v